Biotechnology company MEKanistic Therapeutics announced on Tuesday that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug application for MTX-531, its lead oncology candidate.
Subject to standard start-up activities, MEKanistic may now proceed with its planned Phase 1 clinical study of MTX-531.
MTX-531 is a potential first-in-class small molecule designed to selectively inhibit PI3K and EGFR, two signalling pathways implicated in tumour growth, survival, and adaptive resistance.
The Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumour activity of MTX-531 in patients with advanced solid tumours with dysregulated EGFR and/or PI3K signalling, including head and neck and endometrial cancers. The study is planned to include dose-escalation with expansion cohorts at multiple US sites, with dosing of the first patient anticipated in the third quarter of 2026.
FDA approves MEKanistic Therapeutics' IND for MTX-531
Matter Bio submits first IND application for Lm-LLO-TT
Hansa Biopharma signs EUR115m IDEFIRIX licensing deal with SERB
Lupin receives tentative FDA approval for Revefenacin Inhalation Solution
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System
AstraZeneca wins US approval for Baxfendy as first aldosterone synthase inhibitor for hypertension
Akeso reports results from Phase II trial of ligufalimab combination therapy in AML
US FDA approves Datar Cancer Genetics' comprehensive genomic profiling assay for solid tumours